Alpha 2.0

» Articles » PMID: 34140107

Triglycerides and Residual Atherosclerotic Risk

Overview

Overview

Journal J Am Coll Cardiol

Specialty Cardiology & Vascular Diseases

Date 2021 Jun 18

PMID 34140107

Citations 65

Authors

Authors

Sergio Raposeiras-Roubin

Xavier Rossello

Belen Oliva

Leticia Fernandez-Friera

Jose M Mendiguren

Vicente Andres

Hector Bueno

Javier Sanz

Vicente Martinez De Vega

Emad Abu-Assi

Andres Iniguez

Antonio Fernandez-Ortiz

Borja Ibanez

Valentin Fuster

Affiliations

Affiliations

Soon will be listed here.

Abstract

Background: Even when low-density lipoprotein-cholesterol (LDL-C) levels are lower than guideline thresholds, a residual risk of atherosclerosis remains. It is unknown whether triglyceride (TG) levels are associated with subclinical atherosclerosis and vascular inflammation regardless of LDL-C.

Objectives: This study sought to assess the association between serum TG levels and early atherosclerosis and vascular inflammation in apparently healthy individuals.

Methods: An observational, longitudinal, and prospective cohort study, including 3,754 middle-aged individuals with low to moderate cardiovascular risk from the PESA (Progression of Early Subclinical Atherosclerosis) study who were consecutively recruited between June 2010 and February 2014, was conducted. Peripheral atherosclerotic plaques were assessed by 2-dimensional vascular ultrasound, and coronary artery calcification (CAC) was assessed by noncontrast computed tomography, whereas vascular inflammation was assessed by fluorine-18 fluorodeoxyglucose uptake on positron emission tomography.

Results: Atherosclerotic plaques and CAC were observed in 58.0% and 16.8% of participants, respectively, whereas vascular inflammation was evident in 46.7% of evaluated participants. After multivariate adjustment, TG levels ≥150 mg/dl showed an association with subclinical noncoronary atherosclerosis (odds ratio [OR]: 1.35; 95% confidence interval [CI]: 1.08 to 1.68; p = 0.008). This association was significant for groups with high LDL-C (OR: 1.42; 95% CI: 1.11 to 1.80; p = 0.005) and normal LDL-C (OR: 1.85; 95% CI: 1.08 to 3.18; p = 0.008). No association was found between TG level and CAC score. TG levels ≥150 mg/dl were significantly associated with the presence of arterial inflammation (OR: 2.09; 95% CI: 1.29 to 3.40; p = 0.003).

Conclusions: In individuals with low to moderate cardiovascular risk, hypertriglyceridemia was associated with subclinical atherosclerosis and vascular inflammation, even in participants with normal LDL-C levels. (Progression of Early Subclinical Atherosclerosis [PESA]; NCT01410318).

Citing Articles

Associations between the cardiometabolic index and atherosclerotic cardiovascular disease acorss different glucose metabolism statuses: insights from NHANES, 1999-2020.

Wei Q, Cheng X, Li M, Wu K, Chen M, Zhang D Lipids Health Dis. 2025; 24(1):93.

PMID: 40089751 DOI: 10.1186/s12944-025-02508-7.

Association between obstructive sleep apnea hypopnea syndrome and arteriosclerosis in patients with type 2 diabetes mellitus: mediating effect of blood pressure.

Wang X, Huang X, Xing Y, Jiang X, Hua F Front Endocrinol (Lausanne). 2025; 16:1510737.

PMID: 40013309 PMC: 11860091. DOI: 10.3389/fendo.2025.1510737.

The Role of mtDNA Mutations in Atherosclerosis: The Influence of Mitochondrial Dysfunction on Macrophage Polarization.

Fedotova E, Berezhnov A, Popov D, Shitikova E, Vinokurov A Int J Mol Sci. 2025; 26(3).

PMID: 39940788 PMC: 11817597. DOI: 10.3390/ijms26031019.

Interplay between BMI, neutrophil, triglyceride and uric acid: a case-control study and bidirectional multivariate mendelian randomization analysis.

Lyu H, Fan N, Wen H, Zhang X, Mao H, Bian Q Nutr Metab (Lond). 2025; 22(1):7.

PMID: 39876024 PMC: 11776270. DOI: 10.1186/s12986-025-00896-2.

U-shaped association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and mortality risk in obese adults: evidence from NHANES 1999-2018.

Lin Z, Yi T, Hu F, Chen J, Chen L Front Cardiovasc Med. 2025; 11:1524465.

PMID: 39866802 PMC: 11759299. DOI: 10.3389/fcvm.2024.1524465.

References

1.

Criqui M, Kamineni A, Allison M, Ix J, Carr J, Cushman M . Risk factor differences for aortic versus coronary calcified atherosclerosis: the multiethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2010; 30(11):2289-96. PMC: 2959146. DOI: 10.1161/ATVBAHA.110.208181. View

2.

Chapman M, Ginsberg H, Amarenco P, Andreotti F, Boren J, Catapano A . Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011; 32(11):1345-61. PMC: 3105250. DOI: 10.1093/eurheartj/ehr112. View

3.

Fernandez-Friera L, Fuster V, Lopez-Melgar B, Oliva B, Sanchez-Gonzalez J, Macias A . Vascular Inflammation in Subclinical Atherosclerosis Detected by Hybrid PET/MRI. J Am Coll Cardiol. 2019; 73(12):1371-1382. DOI: 10.1016/j.jacc.2018.12.075. View

4.

Ridker P, Danielson E, Fonseca F, Genest J, Gotto Jr A, Kastelein J . Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195-207. DOI: 10.1056/NEJMoa0807646. View

5.

Fernandez-Ortiz A, Jimenez-Borreguero L, Penalvo J, Ordovas J, Mocoroa A, Fernandez-Friera L . The Progression and Early detection of Subclinical Atherosclerosis (PESA) study: rationale and design. Am Heart J. 2013; 166(6):990-8. DOI: 10.1016/j.ahj.2013.08.024. View

6.

J Blake G, Ridker P, M Kuntz K . Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. Am J Med. 2003; 114(6):485-94. DOI: 10.1016/s0002-9343(03)00074-3. View

7.

Nordestgaard B, Varbo A . Triglycerides and cardiovascular disease. Lancet. 2014; 384(9943):626-635. DOI: 10.1016/S0140-6736(14)61177-6. View

8.

Fernandez-Friera L, Fuster V, Lopez-Melgar B, Oliva B, Garcia-Ruiz J, Mendiguren J . Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. J Am Coll Cardiol. 2017; 70(24):2979-2991. DOI: 10.1016/j.jacc.2017.10.024. View

9.

Agatston A, Janowitz W, HILDNER F, Zusmer N, VIAMONTE Jr M, Detrano R . Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15(4):827-32. DOI: 10.1016/0735-1097(90)90282-t. View

10.

Luscher T . Inflammation and features of the vulnerable plaque: from mechanisms and imaging to outcomes. Eur Heart J. 2020; 41(31):2923-2927. DOI: 10.1093/eurheartj/ehaa686. View

11.

Ridker P, Everett B, Thuren T, MacFadyen J, Chang W, Ballantyne C . Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017; 377(12):1119-1131. DOI: 10.1056/NEJMoa1707914. View

12.

Ference B, Kastelein J, Ray K, Ginsberg H, Chapman M, Packard C . Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA. 2019; 321(4):364-373. PMC: 6439767. DOI: 10.1001/jama.2018.20045. View

13.

Mach F, Baigent C, Catapano A, Koskinas K, Casula M, Badimon L . 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; 41(1):111-188. DOI: 10.1093/eurheartj/ehz455. View

14.

Ingelsson E, Schaefer E, Contois J, McNamara J, Sullivan L, Keyes M . Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007; 298(7):776-85. DOI: 10.1001/jama.298.7.776. View

15.

Serhan C . Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014; 510(7503):92-101. PMC: 4263681. DOI: 10.1038/nature13479. View

16.

Varbo A, Benn M, Tybjaerg-Hansen A, Nordestgaard B . Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013; 128(12):1298-309. DOI: 10.1161/CIRCULATIONAHA.113.003008. View

17.

Boren J, Chapman M, Krauss R, Packard C, Bentzon J, Binder C . Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020; 41(24):2313-2330. PMC: 7308544. DOI: 10.1093/eurheartj/ehz962. View

18.

Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S . Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2006; 115(4):450-8. DOI: 10.1161/CIRCULATIONAHA.106.637793. View

19.

Touboul P, Hennerici M, Meairs S, Adams H, Amarenco P, Desvarieux M . Mannheim intima-media thickness consensus. Cerebrovasc Dis. 2004; 18(4):346-9. DOI: 10.1159/000081812. View

20.

Rossello X, Fuster V, Oliva B, Sanz J, Fernandez Friera L, Lopez-Melgar B . Association Between Body Size Phenotypes and Subclinical Atherosclerosis. J Clin Endocrinol Metab. 2020; 105(12). PMC: 7521861. DOI: 10.1210/clinem/dgaa620. View